Trials / Unknown
UnknownNCT05698160
Biomarkers and Prediction of Tigecycline Induced Coagulation Dysfunction
Biomarkers and Prediction of Tigecycline Induced Coagulation Dysfunction Based on Multi-omics and Machine Learning Techbology
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is to screen out the biomarkers and establish the model to predict coagulation dysfunction induced tigecycline
Detailed description
The critically ill patients treated with tigecycline in in tensive care unit will be recruited and divided into tigecycline-induced coagulation dysfunction group and non-coagulation dysfunction group. The multi-omics will be used to screen out biomarkers for early prediction of coagulation dysfunction caused by tigecycline. Afterwards, machine learning methods will be adopted to establish the the early prediction model of tigecycline-induced coagulation dysfunction.
Conditions
Timeline
- Start date
- 2023-05-01
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
- First posted
- 2023-01-26
- Last updated
- 2023-04-19
Source: ClinicalTrials.gov record NCT05698160. Inclusion in this directory is not an endorsement.